Marker Therapeutics, Inc. (NASDAQ:MRKR) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) have been given a consensus recommendation of “Moderate Buy” by the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $11.25.

MRKR has been the subject of a number of recent research reports. Wall Street Zen raised shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Marker Therapeutics in a report on Monday, December 22nd. Zacks Research downgraded Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. HC Wainwright began coverage on Marker Therapeutics in a report on Monday, December 8th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, UBS Group reissued a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th.

Institutional Investors Weigh In On Marker Therapeutics

A number of institutional investors have recently made changes to their positions in MRKR. Jane Street Group LLC bought a new stake in shares of Marker Therapeutics during the second quarter valued at approximately $33,000. Virtu Financial LLC purchased a new position in shares of Marker Therapeutics in the third quarter worth $25,000. Two Sigma Investments LP purchased a new stake in shares of Marker Therapeutics during the third quarter valued at $33,000. Boyer Financial Services Inc. purchased a new stake in shares of Marker Therapeutics during the 4th quarter valued at about $57,000. Finally, XTX Topco Ltd grew its position in Marker Therapeutics by 166.6% in the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after purchasing an additional 36,269 shares during the period. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Price Performance

MRKR opened at $1.44 on Friday. Marker Therapeutics has a one year low of $0.81 and a one year high of $4.07. The business has a 50 day simple moving average of $1.66 and a two-hundred day simple moving average of $1.27. The firm has a market capitalization of $24.00 million, a price-to-earnings ratio of -1.17 and a beta of 1.42.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.